Skip to Content

ZMapp Approval Status

FDA Approved: No
Brand name: ZMapp
Company: Mapp Biopharmaceutical, Inc.
Treatment for: Ebola Virus Disease

ZMapp is a combination of three chimeric monoclonal antibodies manufactured in the Nicotiana benthamiana tobacco plant. It has been used in the experimental treatment of Ebola virus disease.

Development Status and FDA Approval Process for ZMapp

DateArticle
Sep 17, 2015Experimental Ebola Treatment ZMapp is Granted Fast Track Status by the FDA
Feb 27, 2015LeafBio Announces Acceptance of Investigational New Drug (IND) Application for Ebola Therapy ZMapp

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide